PRE - Prenetics Short-Term Debt to Capital

Prenetics Global Ltd - graphic logo of issuer PRE

Prenetics Global (PRE) maintains moderate pricing power within the genetics segment, shifting its focus from CircleDNA toward innovative cancer screening. This chart of the company's market value on GURU.Markets reflects the 0.01 metric. The business generates revenue by providing personalized health data to individuals and clinics, offering paid diagnostic services and biological sample analysis to identify pathology risks.

Short-Term Debt to Capital Ratio: Prenetics Global (PRE) for 04/28/2023 - 10/29/2026

Analytical breakdowns for Prenetics Global Ltd (PRE)

- stock quotes and analyst forecast:
Stock Price Prenetics Global|PRE - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Prenetics Global Limited|PRE - Enterprise Value
- book capitalization information:
Net Assets per Single Share Prenetics|PRE - Accounting Capitalization|Market Capitalization to Book Value Ratio prenetics.com|PRE - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Prenetics Global|PRE - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Prenetics Global|PRE - Company Cumulative Debt|Debt to Book Capitalization Ratio Prenetics Global Limited|PRE - Long-Term Debt Volume|Company Short-Term Debts Prenetics|Quick Liquidity prenetics.com
- company profitability and valuation multiples indicators:
PRE - Net Financial Result
Analysis of all company metrics:PRE Prenetics
Signature product of prenetics.com

Prenetics Global is investing in DNA analysis automation, which requires significant operating expenses. An analysis of the current short-term debt to equity ratio on the GURU.Markets platform allows for an assessment of short-term liabilities relative to equity. This trend captures the actual rate of liquidity drain, separating the factual debt load from management's declarations. This helps the investor determine whether a systemic degradation of capital value is hidden behind the share price.

Main competitors

Short-Term Debt to Capital A|Quest Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital ILMN (Illumina, Inc.)|Short-Term Debt to Capital exactsciences.com EXAS|RVTY - Short-Term Debt to Equity|BIO (Bio-Rad Laboratories, Inc.) - Short-Term Debt to Capital Ratio|NNNN: Short-Term Debt to Capital|Nordion (SHC) - Short-Term Debt to Capital|Short-Term Debt to Equity QuidelOrtho|Short-Term Debt to Equity OPK|Short-Term Debt to Equity Ratio CDNA (CareDx Health)|MRVI - Current Liabilities to Capital|Short-Term Debt to Equity Fulgent Corp FLGT|Short-Term Debt to Capital Coefficient Standard BioTools Corp (LAB)|Cytek Biosciences, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient orasure.com OSUR|exagen.com (XGN) - Short-Term Debt to Equity|MDXH - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lucid Diagnostics Inc|Insight Molecular - Current Liabilities to Equity|Short-Term Debt to Equity Trinity Biotech plc (TRIB)|PRPH (prophaselabs.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AIMD (Ainos)|Co-Diagnostics Inc (CODX) - Current Liabilities to Capital|HSCS - Short-Term Debt to Equity|BMRA (Biomerica Inc) - Short-Term Debt to Capital Ratio|CDIO: Short-Term Debt to Capital|Current Liabilities to Capital viraxbiolabs.com (VRAX)|Short-Term Debt to Equity Ratio BJDX|AWH (Aspira Women's Health, Inc.) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital AXDX|Short-Term Debt to Capital Coefficient Centogene|Short-Term Debt to Capital ENZ (Enzo Biochem)|FRES - Short-Term Debt to Equity Ratio|GENE - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient 23andMe Holding Co ME|PMD (Psychemedics Corp) - Short-Term Debt to Equity Ratio